Haloperidol Supported for ICU Delirium Treatment, Not Prevention
This dual Bayesian and frequentist meta-analysis clarifies where haloperidol earns a place in ICU delirium care, favoring active treatment over routine prophylaxis.
📅 Journal publication: Mar 20, 2025·Last updated: Sep 26, 2026
haloperidolantipsychoticsdeliriumICUcritical caremortalitybenzodiazepine sparingQTc prolongationBayesian meta-analysissedationCritical Care / ICU
Background Information
Haloperidol effective for delirium symptoms, not for prevention or mortality.
Delirium is a common and serious issue in critical care settings that impacts patient outcomes and mortality. Both Bayesian and frequentist meta-analyses suggest that haloperidol does not significantly reduce mortality or prevent delirium but can be effective in treating delirium symptoms. While haloperidol may help with delirium symptoms, its use does not impact overall mortality or prevention, indicating a need for alternative strategies. Haloperidol treats delirium but does not affect mortality or prevention.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Cheng SL, Hsu TW, Kao YC, Yu CL, Thompson T, Carvalho AF, Stubbs B, Tseng PT, Hsu CW, Yang FC, Tu YK, Liang CS
Citation:Cheng SL, Hsu TW, Kao YC, et al. Haloperidol in treating delirium, reducing mortality, and preventing delirium occurrence: Bayesian and frequentist meta-analyses. Critical care (London, England). 2025;29(1):126. doi:10.1186/s13054-025-05342-6